A randomized, double-blind clinical trial that compared three widely used anticonvulsants for childhood absence epilepsy established that ethosuximide was the most appropriate first-line therapy for this condition. The study provides guidance for the treatment of this common childhood epilepsy where evidence-based recommendations have previously been lacking.